Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide
Tickers: $PTN
Topics: biotechnology clinical trials drug development
Read the full article at Seeking Alpha
Part of the story Palatin Technologies Reports Q1 2027 Financial Results and Obesity Program Milestones (2 articles)